Reviewing Aerovate Therapeutics (NASDAQ:AVTE) & Alzamend Neuro (NASDAQ:ALZN)

Alzamend Neuro (NASDAQ:ALZN) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for Alzamend Neuro and Aerovate Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1	0	1	0	2.00
Aerovate Therapeutics	0	0	0	0	0.00

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 1,943.80%. Given Alzamend Neuro’s stronger consensus rating and higher probable upside, equities analysts clearly believe Alzamend Neuro is more favorable than Aerovate Therapeutics.

Insider and Institutional Ownership

49.6% of Alzamend Neuro shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Alzamend Neuro has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Alzamend Neuro and Aerovate Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.74%	-200.07%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Earnings & Valuation

This table compares Alzamend Neuro and Aerovate Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77 million	($2.90)	-0.47
Aerovate Therapeutics	N/A	N/A	-$75.52 million	($1.70)	-12.92

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Summary

Alzamend Neuro beats Aerovate Therapeutics on 6 of the 11 factors compared between the two stocks.

About Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.